Diabetic Maculopathy
In an Initial FDA human study of 5 eyes with diabetic retinopathy and progressive vision loss, unresponsive to prior antiVEGF, steroid and laser treatment, all eyes had subjectively improved vision with visual acuity > 3 lines in 3 eyes, and 2 lines in the others, noted 1 week of initiation of treatment and maintained with 6 week injections for the duration of the study (6 months). Visual acuity improved to a larger extent than anatomic improvement by OCT. Clearing of lipid exudates was observed but no improvement in leakage on FA. No toxicity was observed.